Knight Therapeutics Inc.

Toronto Stock Exchange:GUD.TO

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

Canada

Market Cap

USD 417.95 M

Share Price

USD 4.20

Avg Daily Volume

70,614

Change (1 day)

-0.70%

Change (1 year)

4.99%

Change (YTD)

13.05%

Knight Therapeutics Inc. Revenue for the year ending December 31, 2024: USD 258.02 M

Knight Therapeutics Inc. Revenue is USD 258.02 M for the year ending December 31, 2024, a 4.20% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Knight Therapeutics Inc. Revenue for the year ending December 31, 2023 was USD 247.63 M, a 14.34% change year over year.
Knight Therapeutics Inc. Revenue for the year ending December 31, 2022 was USD 216.56 M, a 12.50% change year over year.
Knight Therapeutics Inc. Revenue for the year ending December 31, 2021 was USD 192.49 M, a 22.93% change year over year.
Knight Therapeutics Inc. Revenue for the year ending December 31, 2020 was USD 156.58 M, a 328.80% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

Toronto Stock Exchange: GUD.TO

Knight Therapeutics Inc.

CEO	Ms. Samira Sakhia BCom, CA, CPA, MBA
IPO Date	March 3, 2014
Location	Canada
Headquarters	3400 De Maisonneuve Boulevard West
Employees	745
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.